T
Timothy Chevassut
Researcher at Brighton and Sussex Medical School
Publications - 82
Citations - 2420
Timothy Chevassut is an academic researcher from Brighton and Sussex Medical School. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 21, co-authored 70 publications receiving 1926 citations. Previous affiliations of Timothy Chevassut include University of Sussex & Royal Sussex County Hospital.
Papers
More filters
Journal ArticleDOI
The genetic architecture of multiple myeloma
TL;DR: The following review provides a comprehensive coverage of the genetic and epigenetic events contributing to the initiation and progression of multiple myeloma and where possible these abnormalities have been linked to disease prognosis.
Journal ArticleDOI
Severe Global DNA Hypomethylation Blocks Differentiation and Induces Histone Hyperacetylation in Embryonic Stem Cells
Melany Jackson,Anna Krassowska,Nick Gilbert,Timothy Chevassut,Lesley M. Forrester,J. D. Ansell,Bernard Ramsahoye +6 more
TL;DR: It is shown that successful terminal differentiation is not dependent simply on adequate methylation levels, and there is an absolute requirement that the methylation be delivered by the maintenance enzyme Dnmt1.
Journal ArticleDOI
Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma
Christopher I. Jones,Maria V. Zabolotskaya,A J King,Helen Stewart,Gillian A. Horne,Timothy Chevassut,Sarah F. Newbury +6 more
TL;DR: A biomarker signature using microRNAs extracted from serum, which has potential as a diagnostic and prognostic tool for multiple myeloma, is developed.
Journal ArticleDOI
The epigenetic landscape of acute myeloid leukemia
TL;DR: This review examines the literature surrounding the biology of these epigenetic modifying genes with regard to leukemogenesis and their clinical and prognostic relevance in AML when mutated.
Journal ArticleDOI
DOT1L As a Therapeutic Target for the Treatment of DNMT3A-Mutant Acute Myeloid Leukemia
Rachel E. Rau,Benjamin Rodriguez,Min Luo,Mira Jeong,Allison Rosen,Jason H. Rogers,Carly T. Campbell,Scott R. Daigle,Lishing Deng,Yongcheng Song,Steve M. M. Sweet,Timothy Chevassut,Michael Andreeff,Steven M. Kornblau,Wei Li,Margaret A. Goodell +15 more
TL;DR: It is shown that pharmacologic inhibition of DOT1L resulted in decreased expression of oncogenic canyon-associated genes and led to dose- and time-dependent inhibition of proliferation, induction of apoptosis, cell-cycle arrest, and terminal differentiation in DNMT3A-mutant cell lines in vitro.